HSP70-based anti-cancer immunotherapy.

about

Topical heat shock protein 70 prevents imiquimod-induced psoriasis-like inflammation in mice.A Novel Approach to Anticancer Therapy: Molecular Modules Based on the Barnase:Barstar Pair for Targeted Delivery of HSP70 to Tumor Cells

P2860

Q52721777-274C2D61-E593-4EB2-B4C1-258F7F861D1F Q58568946-EB45C9A2-8ACA-4EE4-8485-6618517F0201

P2860

HSP70-based anti-cancer immunotherapy.

Item

http://www.wikidata.org/entity/Q39688737

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

HSP70-based anti-cancer immunotherapy.

@en

HSP70-based anti-cancer immunotherapy.

@nl

type

Item

label

HSP70-based anti-cancer immunotherapy.

@en

HSP70-based anti-cancer immunotherapy.

@nl

prefLabel

HSP70-based anti-cancer immunotherapy.

@en

HSP70-based anti-cancer immunotherapy.

@nl

P1476

HSP70-based anti-cancer immunotherapy.

@en

P2093

Boris A Margulis

http://www.w3.org/2001/XMLSchema#string

Irina V Guzhova

http://www.w3.org/2001/XMLSchema#string

P2860

Immune Evasion Strategies of Glioblastoma

Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial

Heat shock protein vaccines against glioblastoma: from bench to bedside

Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B.

Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children

A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.

Tumor response to mTHPC-mediated photodynamic therapy exhibits strong correlation with extracellular release of HSP70.

HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers.

The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy.

Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.

P304

2529-2535

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2016.1190057

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27294301

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5084976

http://www.w3.org/2001/XMLSchema#string

HSP70-based anti-cancer immunotherapy.

about

P2860

P2860

HSP70-based anti-cancer immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932